Latest Research on Lactobacillus Rhamnosus Probiotics for Weight Loss

Lactobacillus acidophilus strain GOLDGUT-LA100 with bile salt hydrolase activity for lowering cholesterol, blood glucose, and body weight. The strain is isolated from human intestines, identified by 16S rDNA sequencing, and characterized by high bile salt hydrolase activity and gastric acid tolerance. It reduces serum cholesterol, body weight, and liver fat in animal models, and modulates macrophage infiltration in adipose tissue. The strain is suitable for development of probiotic products for lipid lowering, blood glucose control, and weight management.

Source

Lactobacillus rhamnosus strain HOM1213, its fermentation product, and live bacterial preparation, exhibiting anti-oxidation, anti-aging, blood sugar lowering, and immune system enhancing properties. The strain is isolated and characterized through genetic analysis and shown to exhibit superior survival in simulated gastrointestinal conditions compared to commercial strains. The fermentation product and live bacterial preparation are prepared through a freeze-drying process and demonstrated to possess antioxidant and anti-inflammatory activities, as well as the ability to stimulate insulin secretion and improve glucose metabolism.

Source

Probiotics with modified energy metabolism that regulate lipid absorption in the gut, comprising bacteria engineered through stress-based directed evolution to either metabolize or store lipids before absorption, thereby reducing body weight in subjects with obesity or overweight conditions.

Source

A probiotics composition for weight loss, lipid reduction, blood pressure management, liver protection, and Helicobacter pylori inhibition, comprising a combination of probiotics, prebiotics, and green tea extract that modulates gut microbiota to promote metabolic health.

Source

Methods and compositions for treating weight-related disorders by altering the gut microbiota. The methods involve administering microbiota from specific bacterial phyla, orders, or genera to increase their relative abundance in the gut, thereby promoting weight loss and improving metabolic health. The compositions can include live bacterial strains or compounds that selectively increase or decrease specific microbiota populations. The methods can be used as a standalone treatment or in combination with other therapies, including surgery, to manage obesity and related metabolic disorders.

Source

Compositions comprising a probiotic combination of two or more bacterial strains from different species, including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus rhamnosus, and Bifidobacterium lactis, for preventing and treating metabolic syndrome and related disorders. The combination is particularly effective when comprising Lactobacillus gasseri and Bifidobacterium lactis, and has been shown to reduce cholesterol, triglycerides, and waist circumference, while also lowering inflammatory markers.

Source

A composition for improving intestinal microbial populations and reducing body weight, comprising galactose, which increases the proportion of beneficial bacteria such as Akkermansia, Lactobacillus, and Alistipes, and is used for preventing and treating obesity.

Source

A system for designing personalized microbiome therapeutics and diet based on functions of an individual's microbiome. The system analyzes gut microbiome composition and function to identify dysbiotic states and perturbed metabolic pathways. It generates personalized therapeutic recommendations, including probiotics, prebiotics, and dietary interventions, based on the individual's microbiome profile and functional deficits.

Source

Probiotic supplementation has been identified as a potential target to reduce inflammatory mediators associated with obesity. Therefore, this study assessed the effect of probiotic

Source

Lactobacillus plantarum KU15120 strain with antioxidant and anti-obesity properties, isolated from radish kimchi, exhibits probiotic characteristics including acid resistance, bile tolerance, and intestinal adhesion. The strain inhibits adipocyte differentiation and reduces triglyceride content, making it a potential functional food ingredient for preventing or treating obesity.

Source

A novel Lactobacillus helveticus strain, BCC-LH-04, with body fat reduction activity, and compositions containing the same, for preventing or treating obesity. The strain inhibits preadipocyte differentiation, reduces fatty acid concentration, produces extracellular polysaccharides, and inhibits lipase enzyme activity. Compositions include pharmaceutical, health functional food, and quasi-drug formulations containing the BCC-LH-04 strain or its culture.

Source

Gut microbiota influences energy homeostasis in part through circulating hormones. Insulin-like growth factor-binding protein (IGFBP)-2 is a biomarker whose increase in systemic circulation is associated with positive effects on body weight and metabolism. In a recent clinical trial, probiotic Lacticaseibacillus rhamnosus HA-114 supplementation showed positive effects on eating behaviors and insulin resistance in overweight participants undergoing a weight-loss intervention. In this context, this ancillary study aimed at assessing the impact of L. rhamnosus HA-114 supplementation on plasma IGFBP-2 levels in these individuals, and whether this modulation correlated with changes in fat mass, energy metabolism, and eating behaviors. Fasting plasma IGFBP-2 concentrations were quantified in 100 overweight or obese men and women enrolled in a 12-week diet-based weight reduction program (500 kcal/day), in combination with probiotic L. rhamnosus HA-114 or placebo supplementation. Baseline and changes in circulating IGFBP-2 concentrations were correlated with anthropometric parameter, glucos... Read More

Source

Abstract Background The prevalence of excess weight and obesity is increasing in an extremely concerning manner worldwide, with highly diverse therapies for current treatment. This review evaluated the scientific evidence of the past 10 years on the use of probiotics in treating excess weight and obesity in the absence of dieting. Materials A systematic review was conducted by searching for clinical trials on humans published in English in the PubMed, Scopus and Cochrane Central databases, using the combination of keywords Overweight, Probiotics and Obesity, and published between 2012 and 2022. Results Six published studies met the inclusion criteria. The review showed that, although there is a lack of consensus in the literature, the use of probiotics in the absence of dieting produced a significant reduction in body weight and body mass index in 66.6% of the reviewed studies, a significant reduction in waist circumference in 80.0% of the reviewed studies, and an improvement in total body fat mass and waist circumference. Conclusions This review showed evidence of a trend in p... Read More

Source

The fermented yogurt of Lacticaseibacillus rhamnosus HF01 alters obese mice gut microbiota by boosting beneficial flora and butyric acid, activates AMPK to regulate lipid metabolism, combating obesity.

Source

Introduction: the gut microbiota is a potential determining factor in the development of obesity, resulting in dysbiosis, which is related to a lower number of members of the Bacteroidetes division and an increase in Firmicutes leading to a decrease in energy expenditure, it is also associated with the inflammatory process, insulin resistance and type 2 diabetes mellitus. Objective: to carry out a literature review related to the effects of probiotics on the improvement of the intestinal microbiota in an obese patient and its associated disorders.Methods: a search of articles in PubMed, Google Scholar and Elsevier from the last five years was carried out using the terms "obesity and probiotics", "effect of probiotics", "gut microbiota and probiotics". A total of 23 articles were included in the selection criteria. Results: supplementation with probiotics specifically certain strains such as Lactobacillus plantarum and Bifidobacterium could lead to significant weight reductions, in combination with energy restriction and physical activity. However, it is important to develop clinical ... Read More

Source

A combination of vitamin C and Lactobacillus rhamnosus, particularly Lactobacillus rhamnosus GG, for improving gut health by increasing butyrate levels in the large intestine. The combination can be administered orally, preferably in a delayed-release formulation, to enhance the beneficial effects of butyrate on gut health and prevent or treat conditions such as irritable bowel syndrome, inflammatory bowel disease, and obesity.

Source

A probiotic bacterial strain, Lactiplantibacillus plantarum IMC 510, isolated from human origin, for use in preventing and treating overweight and obesity. The strain, deposited at DSMZ under DSM 32548, exhibits probiotic properties and is effective in reducing body weight, BMI, waist circumference, and fat mass in overweight and obese individuals.

Source

Preventing and treating metabolic diseases like obesity using a combination of a Lactobacillus fermentum strain and a metabolic regulator. The Lactobacillus strain improves efficacy and reduces side effects of metabolic regulators like GLP-1 analogues. The combination provides better outcomes for obesity treatment compared to using just the metabolic regulator alone.

Source

The status of an impaired gut microbial community, known as dysbiosis, is associated with metabolic diseases such as obesity and insulin resistance. The use of probiotics has been considered an effective approach for the treatment and prevention of obesity and related gut microbial dysbiosis. The anti-obesity effect of Lacticaseibacillus paracasei AO356 was recently reported. However, the effect of L. paracasei AO356 on the gut microbiota has not yet been identified. This study aimed to elucidate the effect of L. paracasei AO356 on gut microbiota and ensure its safety for use as a probiotic.Oral administration of L. paracasei AO356 (107 colony-forming units [CFU]/mg per day, 5 days a week, for 10 weeks) to mice fed a high-fat diet significantly suppressed weight gain and fat mass. We investigated the composition of gut microbiota and explored its association with obesity-related markers.Oral administration of L. paracasei AO356 significantly changed the gut microbiota and modified the relative abundance of Lactobacillus, Bacteroides, and Oscillospira. Bacteroides and Oscillospira wer... Read More

Source

Regulating lipid absorption to prevent weight gain after dietary restriction. The method involves adjusting intestinal bacteria and metabolites to increase lipid absorption. This can be done by increasing levels of specific bacteria like Lactobacillus or metabolites like DL-3-phenyllactic acid, 4-hydroxyphenyllactic acid, indolelactic acid, 2-hydroxyisocaproic acid, and 2-hydroxy-3-methylbutyric acid in the digestive tract. Alternatively, reducing levels of these bacteria or metabolites can decrease lipid absorption. This can be achieved by antibiotics to clear gut flora, high protein diet, or restricting diet before reintroduction.

Source